CN108047349A - 一种卷边桩菇多糖提取物及其制备方法和医用用途 - Google Patents
一种卷边桩菇多糖提取物及其制备方法和医用用途 Download PDFInfo
- Publication number
- CN108047349A CN108047349A CN201810024951.0A CN201810024951A CN108047349A CN 108047349 A CN108047349 A CN 108047349A CN 201810024951 A CN201810024951 A CN 201810024951A CN 108047349 A CN108047349 A CN 108047349A
- Authority
- CN
- China
- Prior art keywords
- paxillus
- involute
- involute paxillus
- polyoses extract
- polysaccharide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000222543 Paxillus Species 0.000 title claims abstract description 67
- 239000000284 extract Substances 0.000 title claims abstract description 49
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 238000000605 extraction Methods 0.000 title claims abstract description 7
- 150000004676 glycans Chemical class 0.000 claims abstract description 27
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 26
- 239000005017 polysaccharide Substances 0.000 claims abstract description 26
- 239000003814 drug Substances 0.000 claims abstract description 12
- 238000001556 precipitation Methods 0.000 claims abstract description 12
- 101150037263 PIP2 gene Proteins 0.000 claims abstract description 7
- 101100262439 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) UBA2 gene Proteins 0.000 claims abstract description 7
- 229940079593 drug Drugs 0.000 claims abstract description 7
- 239000000243 solution Substances 0.000 claims description 25
- 101150017682 PIP2-1 gene Proteins 0.000 claims description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 18
- 239000008103 glucose Substances 0.000 claims description 12
- 239000006228 supernatant Substances 0.000 claims description 12
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 239000008367 deionised water Substances 0.000 claims description 9
- 229910021641 deionized water Inorganic materials 0.000 claims description 9
- 238000010828 elution Methods 0.000 claims description 7
- 235000019441 ethanol Nutrition 0.000 claims description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- 238000012869 ethanol precipitation Methods 0.000 claims description 6
- -1 galactolipin Chemical compound 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 claims description 4
- 230000003064 anti-oxidating effect Effects 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 241000894006 Bacteria Species 0.000 claims description 3
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 3
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 claims description 3
- 101000929940 Homo sapiens Adrenocortical dysplasia protein homolog Proteins 0.000 claims description 3
- 101000730577 Homo sapiens p21-activated protein kinase-interacting protein 1 Proteins 0.000 claims description 3
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 claims description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 3
- 238000005119 centrifugation Methods 0.000 claims description 3
- 239000003153 chemical reaction reagent Substances 0.000 claims description 3
- 238000004440 column chromatography Methods 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 210000003061 neural cell Anatomy 0.000 claims description 3
- 229920001542 oligosaccharide Polymers 0.000 claims description 3
- 150000002482 oligosaccharides Chemical class 0.000 claims description 3
- 102100032579 p21-activated protein kinase-interacting protein 1 Human genes 0.000 claims description 3
- 238000000746 purification Methods 0.000 claims description 3
- 150000003384 small molecules Chemical class 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- 239000001117 sulphuric acid Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 238000004108 freeze drying Methods 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 230000007365 immunoregulation Effects 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000008188 pellet Substances 0.000 claims 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 abstract description 9
- 239000003963 antioxidant agent Substances 0.000 abstract description 9
- 230000003078 antioxidant effect Effects 0.000 abstract description 9
- 235000006708 antioxidants Nutrition 0.000 abstract description 9
- 210000002569 neuron Anatomy 0.000 abstract description 9
- 230000033228 biological regulation Effects 0.000 abstract description 7
- 230000001900 immune effect Effects 0.000 abstract description 7
- 241000233866 Fungi Species 0.000 abstract description 4
- 235000009508 confectionery Nutrition 0.000 abstract description 2
- 238000011161 development Methods 0.000 abstract description 2
- 230000001151 other effect Effects 0.000 abstract description 2
- 238000011160 research Methods 0.000 abstract description 2
- 230000004071 biological effect Effects 0.000 abstract 1
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 9
- 230000002000 scavenging effect Effects 0.000 description 9
- 238000002835 absorbance Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 4
- 108090001005 Interleukin-6 Proteins 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000011987 methylation Effects 0.000 description 3
- 238000007069 methylation reaction Methods 0.000 description 3
- 239000012028 Fenton's reagent Substances 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000007640 basal medium Substances 0.000 description 2
- 230000008033 biological extinction Effects 0.000 description 2
- 238000001212 derivatisation Methods 0.000 description 2
- 238000009509 drug development Methods 0.000 description 2
- 125000005909 ethyl alcohol group Chemical group 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000000413 hydrolysate Substances 0.000 description 2
- 230000031700 light absorption Effects 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 description 1
- 241000222485 Agaricales Species 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 241000221198 Basidiomycota Species 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 240000008397 Ganoderma lucidum Species 0.000 description 1
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 1
- 241001248610 Ophiocordyceps sinensis Species 0.000 description 1
- 241001233115 Paxillus involutus Species 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical class OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
- 239000012496 blank sample Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 239000011344 liquid material Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 239000011806 microball Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- USHAGKDGDHPEEY-UHFFFAOYSA-L potassium persulfate Chemical compound [K+].[K+].[O-]S(=O)(=O)OOS([O-])(=O)=O USHAGKDGDHPEEY-UHFFFAOYSA-L 0.000 description 1
- 150000003232 pyrogallols Chemical class 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0003—General processes for their isolation or fractionation, e.g. purification or extraction from biomass
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Materials Engineering (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Sustainable Development (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明提供一种卷边桩菇多糖提取物及其制备方法和医用用途，从天然菌物卷边桩菇中获得具有新颖结构和多种生物活性的多糖PIP2‑1；并在该多糖制备过程中创造性的增加了两次80%乙醇沉淀步骤改进了卷边桩菇粗多糖的溶解性和纯度，同时公开了该多糖具有抗氧化、免疫调节和保护神经细胞等功效，可用于制备治疗抗氧化、免疫调节和保护神经细胞的药物，为卷边桩菇后续的开发和利用提供研究基础，具有重要的经济价值和市场价值。
Description
技术领域
本发明涉及一种卷边桩菇多糖提取物，具有抗氧化，免疫调节，保护神经细胞作用，本发明进一步提供了其制备方法，属于天然药物开发领域。
背景技术
随着生活水平的提高，人们逐渐增强了保健意识。另一方面，由于饮食不健康，工作压力大，环境污染，这些因素会使免疫力下降以及自由基增多而导致的氧化损伤等健康问题，随着年龄增长这些因素也是导致老年痴呆的原因之一。因此，开发具有抗氧化，免疫调节和保护神经细胞作用的药物或功能食品成为当务之急。
大型真菌是一种重要的天然生物资源，包括灵芝，虫草等在内的大型真菌由于其药效显著，副作用少，已成为药物开发的重要资源。卷边桩菇（Paxillus involutus），所属担子菌纲，伞菌目，广泛分布于北半球。“长白山植物药志”记录追风散寒，舒筋活络。主治手足麻木，筋络不舒，腰腿疼痛”。而目前，对卷边桩菇抗氧化，免疫调节和保护神经细胞等功能的开发未见报道。因此，对其进行药用价值的开发和利用具有重要意义。
发明内容
本发明涉及一种卷边桩菇多糖提取物，具有抗氧化，免疫调节，保护神经细胞作用，本发明进一步提供了其制备方法，
本发明所述的一种卷边桩菇多糖提取物，其特征在于由卷边桩菇通过乙醇提取得到。
本发明所述的卷边桩菇多糖提取物，其特征在于：卷边桩菇多糖提取物含量为82.96%，蛋白含量为3.1%，分子量为32 kDa；
该多糖由葡萄糖，甘露糖，半乳糖，岩藻糖组成，比例分别为62.2%, 2.8%，25.4%和9.6%；连接方式为T-岩藻糖、1,3-甘露糖、T-葡萄糖、1,4-葡萄糖、1,6葡萄糖、T-半乳糖、1,6-半乳糖、1,4,6-半乳糖及1,2,6-半乳糖。
本发明所述的卷边桩菇多糖提取物的制备方法，包括如下步骤：
1）将卷边桩菇烘干，粉碎过200目筛，将卷边桩菇菌粉在79℃，液料比为43.1 mL/g条件下提取3 h；提取液浓缩至原浓度1/5~1/4，加入无水乙醇至终浓度80%，沉淀，5000r/min离心去上清，沉淀烘干后，加入去离子水溶解，再加入终浓度为80%的乙醇沉淀，去上清后，用冷冻干机冷冻干燥备用；
2）将冻干的多糖样品加入去离子水溶解，通过3次sevag试剂(正丁醇：氯仿=1:4，v/v)去蛋白，再通过3500 Da截留量透析袋透析去除小分子，寡糖后浓缩并再通过80%乙醇沉淀，5000r/min离心去上清，沉淀通过冷冻干燥机冷冻干燥获得多糖卷边桩菇初级纯化多糖PIP；
3）将PIP用去离子水溶解，进行DEAE Cellulose-52(5.0×30 cm)柱层析，NaCl浓度由0~1 mol/L梯度洗脱，洗脱速度为1 mL/min，每管收集5 mL，通过苯酚-硫酸法测定多糖含量将含有多糖部分收集，分别获得多糖组分PIP1和PIP2，进一步将PIP2进行Sephadex-G 100(2.6×60 cm)层析，获得卷边桩菇多糖提取物PIP2-1。
本发明所述的卷边桩菇多糖提取物在制备免疫调节药物中的用途。
本发明所述的卷边桩菇多糖提取物在制备抗氧化药物中用途。
本发明所述的卷边桩菇多糖提取物在制备保护神经细胞药物中用途。
本发明所述的一种药物组合物，其特征在于含有如权利要求1或2所述的卷边桩菇多糖提取物提取物和任选地药学上可接受的辅料。
本发明所述的药物组合物，其特征在于为片剂、胶囊剂、滴丸剂、颗粒剂、散剂、微丸、溶液剂、糖浆剂、乳剂或注射剂。
本发明的积极效果在于：首次从天然菌物卷边桩菇中获得具有新颖结构和多种生物活性的多糖PIP2-1；并在该多糖制备过程中创造性的增加了两次80%乙醇沉淀步骤改进了卷边桩菇粗多糖的溶解性和纯度，同时公开了该多糖具有抗氧化、免疫调节和保护神经细胞等功效，可用于制备治疗抗氧化、免疫调节和保护神经细胞的药物，为卷边桩菇后续的开发和利用提供研究基础，具有重要的经济价值和市场价值。
附图说明
图1为本发明卷边桩菇多糖提取物洗脱曲线（A）DEAE Cellulose-52分析，（B）Sephadex-G 100层析；
图2 为本发明PIP2-1单糖组成分析；
图3为本发明PIP2-1体外抗氧化活性；
图4 为本发明PIP2-1对巨噬细胞分泌IL-6和TNFα的影响；（*: 与对照组比p<0.05；**:与对照组比p<0.01）；
图5 为本发明PIP2-1对L-谷氨酸所致的神经细胞PC12 (A)和HT22 (B)损伤的影响（##：与对照组比，p<0.01; *: 与模型组比p<0.05；**: 与模型组比p<0.01）。
具体实施方式
下面结合具体实施例，进一步阐述本发明。应理解，这些实施例仅用于说明本发明而不限制发明范围。此外应理解，在阅读了本发明的内容之后，本领域技术人员可以对发明作各种改动或修改，这些等价形式同样落于本申请所附后权利要求书限定的范围。
实施例1：
卷边桩菇多糖提取物提取物的制备
1、将吉林松原地区采集的卷边桩菇烘干，粉碎过200目筛，将卷边桩菇菌粉在79℃，液料比为43.1 mL/g条件下提取3 h。提取液浓缩至原浓度1/5~1/4，加入无水乙醇至终浓度80%，沉淀，5000r/min离心去上清，沉淀烘干后，加入去离子水溶解，在加入终浓度为80%的乙醇沉淀，去上清后，沉淀用冻干机冷冻干燥备用。
2、将冻干多的多糖样品加入去离子水溶解，通过3次sevag试剂(正丁醇：氯仿=1:4，v/v)去3 蛋白，再通过透析液出去小分子，寡糖后浓缩并通过80%乙醇沉淀，5000r/min离心去上清，沉淀通过冷冻干燥机冷冻干燥获得多糖卷边桩菇初级纯化多糖PIP
3、将PIP用去离子水溶解，进行DEAE Cellulose-52(5.0×30 cm)柱层析，NaCl浓度由0~1 mol/L梯度洗脱，洗脱速度为1 mL/min，每管收集5 mL，通过苯酚-硫酸法测定多糖含量将含有多糖部分收集，分别获得多糖组分PIP1和PIP2（图 1A），进一步将PIP2进行Sephadex-G 100 (2.6×60 cm)层析，获得PIP2-1（图 1B）。
实施例2：
卷边桩菇多糖提取物PIP2-1单糖组成分析
取2 mg多糖样品通过含有1 M HCl的甲醇水解，水解产物通过2M TFA水解后，水解产物通过1-苯基-3-甲基-5-吡唑啉酮（PMP）衍生化后，产物进行Compass C18 column (250 ×4.6 mm) 连接岛津HPLC分析洗脱产物在UV245 nm出检测，结果如图2所示。结果表明，PIP2-1主要由由葡萄糖，甘露糖，半乳糖，岩藻糖组成，比例分别为62.2%,，2.8%，25.4%和9.6%。
实施例3：
卷边桩菇多糖提取物PIP2-1的甲基化分析
5 mg 多糖在氮气条件下溶解在含有NaOH的无水DMSO后，样品用CH3I甲基化，全甲基化产物进一步用2.5 M 三氟乙酸121℃下水解1.5h。衍生化产物在安捷伦GC7890A-MS5975CGC-MS系统上，用 HP-5 ms quartz capillary 柱分析，结果如表1所示，结果表明PIP2-1主要的连接方式为T-岩藻糖, 1,3-甘露糖，T-葡萄糖, 1,4-葡萄糖，1,6葡萄糖，T-半乳糖，1,6-半乳糖，1,4,6-半乳糖，1,2,6-半乳糖。
表1 PIP2-1甲基化分析结果
| Methylation sugar | Retention time (min) | Linkage type | Molar ratio (%) |
| 2,3,4-Me3-Fuc | 14.89 | T-Fuc | 8.8 |
| 2,4,6-Me3-Man | 19.03 | 1,3-Man | 2.0 |
| 2,3,4,6-Me4-Glc | 17.15 | T-Glc | 21.4 |
| 2,3,6-Me3- Glc | 19.33 | 1,4-Glc | 32.2 |
| 2,3,4-Me3-Glc | 19.60 | 1,6-Glc | 4.6 |
| 2,3,4,6-Me4-Gal | 17.61 | T-Gal | 2.9 |
| 2,3,4-Me3-Gal | 20.26 | 1,6-Gal | 14.8 |
| 2,3-Me2-Gal | 21.33 | 1,4,6-Gal | 6.1 |
| 3,4-Me2-Gal | 21.92 | 1,2,6-Gal | 7.1 |
通过以下试验证明本发明卷边桩菇多糖提取物的医用用途：
试验例1：
卷边桩菇多糖提取物PIP2-1具有清除羟自由基，ABTS, DPPH和超氧阴离子作用
分别对卷边桩菇多糖提取物的清除羟自由基，ABTS, DPPH和超氧阴离子能力进行测定，以其说明其抗氧化活性，采用VC作为阳性对照；
清除羟自由基活性实验：取1 mL 0.02M的磷酸盐缓冲液（pH=7）, 0.8mL 0.15 mM亚甲蓝溶液，0.4 mL 0.01M Fe(Ⅱ)-EDTA溶液，0.2 mL 7.5 mM H2O2溶液，加入卷边桩菇多糖提取物溶液（0.2, 0.6, 1.0, 1.2, 1.6, 2.0 mg/mL）0.5 mL，用90%乙醇溶液稀释至10 mL,混匀反应2 h, 测定660 nm处吸光度，A0为初始亚甲蓝溶液的吸光度，A1为加入Fenton试剂后的吸光度，A2为加入Fenton试剂及卷边桩菇多糖提取物溶液后的吸光度。按以下公式计算卷边桩菇多糖提取物对羟自由基的清除能力：
清除率（%）=[1-(A0-A2)/ (A0-A1)]×100%
清除ABTS活性实验：7 mM的ABTS溶液100 mL与2.45 mM的过硫酸钾溶液溶液混合，避光16 h后作为ABTS反应液使用。取1mL ABTS反应液加入100 mL无水乙醇，并用无水乙醇逐级稀释该溶液至OD734为0.7±0.02。将3.9 mL的ABTS反应液分别加入100 μL卷边桩菇多糖提取物溶液（0.2, 0.6, 1.0, 1.2, 1.6, 2.0 mg/mL），或乙醇溶液，避光30 min, 分别测定其吸光度A样品及A空白, 按以下公式计算卷边桩菇多糖提取物对ABTS的清除能力：
清除率（%）=[(A空白-A样品)/ A空白)]×100%
清除DPPH活性方法：0.75 mL的0.1 mM DPPH与1.5 mL不同浓度卷边桩菇多糖提取物（0.2, 0.6, 1.0, 1.2, 1.6, 2.0 mg/mL）溶液混匀，避光30 min，测定无水乙醇在517nm处吸光度A1; 0.75 mL无水乙醇与1.5mL卷边桩菇溶液混匀，避光30 min后，测定517nm处吸光度A2；0.75 mL的0. 1mM DPPH与1.5 mL无水乙醇混匀，避光30 min后，测定517nm处吸光度A0。按以下公式计算卷边桩菇多糖提取物对DPPH自由基的清除能力：清除率（%）=[1-(A1-A2)/A0)]×100%
清除超氧阴离子活性方法：取4 mL Tris-HCl溶液（pH=8.2）, 加入卷边桩菇多糖提取物溶液（0.2, 0.6, 1.0, 1.2, 1.6, 2.0 mg/mL）0.5 mL，采用乙醇定容至10 mL, 48 ℃反应40 min, 加入48 ℃预热后的3 mM 邻苯三酚 0.3 mL,立刻混匀，测定其319.5 nm处吸光度，空白样品的吸光值为A0,加入卷边桩菇多糖提取物后样品的吸光值为A1。按以下公式计算卷边桩菇多糖提取物对超氧阴离子的清除能力：
清除率（%）=[1-A1/A0]×100%
以上四种抗氧化实验结果如图3所示，卷边桩菇多糖提取物PIP2-1对·OH，ABTS, DPPH清除率的IC50值分别为0.1mg/mL，0.92mg/mL和0.38 mg/mL而对超氧阴离子清除能力与阳性药物VC接近显著高于其他同类多糖。
试验例2：
卷边桩菇多糖提取物提取物PIP2-1激活巨噬细胞促进其分泌TNFα和IL-6
取对数生长的小鼠巨噬细胞RAW264.7,采用含有10% FBS和1% biomyc-3的DMEM培养基稀释至1*105个/mL,每孔接种100μL，于37 ℃，10% CO2细胞培养箱中过夜培养。每孔分别加入卷边桩菇多糖提取物PIP2-1（50，100， 200，400μg/mL，由基础培养基配制）,阳性对照孔加入1μg/mL LPS，阴性对照孔加入基础培养基，每孔3个平行。药物处理24h，分别取上清。采用ELISA试剂盒测定上清中细胞因子(IL-6,TNFα)水平。结果如图4所示，卷边桩菇多糖提取物较对照组能够显著刺激小鼠巨噬细胞分泌IL-6和TNFα，结果说明卷边桩菇多糖提取物具有显著的免疫调节活性。
试验例3：
卷边桩菇多糖提取物PIP2-1对L-谷氨酸所致的神经细胞损伤具有保护作用
采用MTT方法，分别取对数生长期的PC12和HT22细胞，用完全培养基将其分别稀释成5*105个/mL的细胞悬液，每孔接种100μL, 于37 ℃，10% CO2细胞培养箱中过夜培养。移去培养基，每孔分别加入100μL不同浓度（10-200 μg/mL）的卷边桩菇多糖提取物PIP2-1（采用基础培养基稀释）处理3h，，再用终浓度为25 μM的L-谷氨酸处理24 h，同时以不加谷氨酸和多糖组为对照组，以只加谷氨酸不加多糖预处理为模型组，每孔加入10μL MTT（5 mg/mL），37 ℃培养箱孵育4 h。弃上清后每孔加入150μL DMSO,均匀震荡，读取540 nm波长吸光度。结果如图5所示，PIP2-1对L-谷氨酸所致的神经细胞PC12和HT22均有显著的保护作用。
Claims (8)
1.一种卷边桩菇多糖提取物（简称：PIP2-1），其特征在于由卷边桩菇通过乙醇提取得到。
2. 如权利要求1所述的卷边桩菇多糖提取物，其特征在于：卷边桩菇多糖提取物含量为82.96%，蛋白含量为3.1%，分子量为32 kDa；
该多糖由葡萄糖，甘露糖，半乳糖，岩藻糖组成，比例分别为62.2%, 2.8%，25.4%和9.6%；连接方式为T-岩藻糖、1,3-甘露糖、T-葡萄糖、1,4-葡萄糖、1,6葡萄糖、T-半乳糖、1,6-半乳糖、1,4,6-半乳糖及1,2,6-半乳糖。
3.如权利要求1-2之一所述的卷边桩菇多糖提取物的制备方法，包括如下步骤：
1）将卷边桩菇烘干，粉碎过200目筛，将卷边桩菇菌粉在79℃，液料比为43.1 mL/g条件下提取3 h；提取液浓缩至原浓度1/5~1/4，加入无水乙醇至终浓度80%，沉淀，5000r/min离心去上清，沉淀烘干后，加入去离子水溶解，在加入终浓度为80%的乙醇沉淀，去上清后，用冷冻干机冷冻干燥备用；
2）将冻干的多糖样品加入去离子水溶解，通过3次sevag试剂(正丁醇：氯仿=1:4，v/v)去蛋白，再通过3500 Da截留量透析袋透析去除小分子，寡糖后浓缩并再通过80%乙醇沉淀，5000r/min离心去上清，沉淀通过冷冻干燥机冷冻干燥获得多糖卷边桩菇初级纯化多糖PIP；
3）将PIP用去离子水溶解，进行DEAE Cellulose-52(5.0×30 cm)柱层析，NaCl浓度由0~1 mol/L梯度洗脱，洗脱速度为1 mL/min，每管收集5 mL，通过苯酚-硫酸法测定多糖含量将含有多糖部分收集，分别获得多糖组分PIP1和PIP2，进一步将PIP2进行Sephadex-G 100(2.6×60 cm)层析，获得卷边桩菇多糖提取物提取物。
4.如权利要求1所述的卷边桩菇多糖提取物在制备免疫调节药物中的用途。
5.如权利要求1所述的卷边桩菇多糖提取物在制备抗氧化药物中用途。
6.如权利要求1所述的卷边桩菇多糖提取物在制备保护神经细胞药物中用途。
7.一种药物组合物，其特征在于含有如权利要求1或2所述的卷边桩菇多糖提取物和任选地药学上可接受的辅料。
8.如权利要求7所述的药物组合物，其特征在于为片剂、胶囊剂、滴丸剂、颗粒剂、散剂、微丸、溶液剂、糖浆剂、乳剂或注射剂。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810024951.0A CN108047349B (zh) | 2018-01-11 | 2018-01-11 | 一种卷边桩菇多糖提取物及其制备方法和医用用途 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810024951.0A CN108047349B (zh) | 2018-01-11 | 2018-01-11 | 一种卷边桩菇多糖提取物及其制备方法和医用用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108047349A true CN108047349A (zh) | 2018-05-18 |
| CN108047349B CN108047349B (zh) | 2020-10-27 |
Family
ID=62127185
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810024951.0A Expired - Fee Related CN108047349B (zh) | 2018-01-11 | 2018-01-11 | 一种卷边桩菇多糖提取物及其制备方法和医用用途 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108047349B (zh) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110642959A (zh) * | 2019-10-17 | 2020-01-03 | 吉林农业大学 | 一种玉木耳酸性多糖及其制备方法和用途 |
| CN115490778A (zh) * | 2022-09-21 | 2022-12-20 | 吉林农业大学 | 一种凤尾菇多糖提取物及其制备方法和应用 |
| CN115746157A (zh) * | 2022-11-24 | 2023-03-07 | 吉林农业大学 | 一种美味扇菇多糖及其制备方法和用途 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101018869A (zh) * | 2004-07-16 | 2007-08-15 | 药用菌类公司 | 来自于真菌的免疫调节组合物 |
| CN103130907A (zh) * | 2013-02-16 | 2013-06-05 | 浙江省林业科学研究院 | 一种中国被毛孢蛋白多糖及其制备和用途 |
| CN103554290A (zh) * | 2013-11-11 | 2014-02-05 | 中国药科大学 | 一种肿节风酸性多糖及其制备方法、应用 |
| CN104507502A (zh) * | 2012-07-23 | 2015-04-08 | 国家科学研究中心 | 基于凝集素的递送系统 |
-
2018
- 2018-01-11 CN CN201810024951.0A patent/CN108047349B/zh not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101018869A (zh) * | 2004-07-16 | 2007-08-15 | 药用菌类公司 | 来自于真菌的免疫调节组合物 |
| CN104507502A (zh) * | 2012-07-23 | 2015-04-08 | 国家科学研究中心 | 基于凝集素的递送系统 |
| CN103130907A (zh) * | 2013-02-16 | 2013-06-05 | 浙江省林业科学研究院 | 一种中国被毛孢蛋白多糖及其制备和用途 |
| CN103554290A (zh) * | 2013-11-11 | 2014-02-05 | 中国药科大学 | 一种肿节风酸性多糖及其制备方法、应用 |
Non-Patent Citations (5)
| Title |
|---|
| ANKUSH BARAD 等: "Anti-proliferative activity of a purified polysaccharide isolated from the basidiomycete fungus Paxillus involutus", 《CARBOHYDRATE POLYMERS》 * |
| HAIHUA YANG 等: "Characterization and antioxidant activity of a novel polysaccharidefrom Pholidota chinensis Lindl.", 《CARBOHYDRATE POLYMERS》 * |
| PENG JIANG 等: "Characterization and antioxidant activities of the polysaccharidesfrom mycelium of Phellinus pini and culture medium", 《CARBOHYDRATE POLYMERS》 * |
| ROSTYSLAV ANTONYUK 等: "Lectin purification from fruiting bodies of brown roll-rim fungus, Paxillus involutus (Fr.) Fr., and its application in histochemistry", 《ROM J MORPHOL EMBRYOL》 * |
| SHOU XIAN WANG等: "purification and Characterization of a Novel Lectin with Antiphytovirus activities from the wild Mushroom Paxillus involutus", 《PROTEIN & PEPTIDE LETTERS》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110642959A (zh) * | 2019-10-17 | 2020-01-03 | 吉林农业大学 | 一种玉木耳酸性多糖及其制备方法和用途 |
| CN115490778A (zh) * | 2022-09-21 | 2022-12-20 | 吉林农业大学 | 一种凤尾菇多糖提取物及其制备方法和应用 |
| CN115746157A (zh) * | 2022-11-24 | 2023-03-07 | 吉林农业大学 | 一种美味扇菇多糖及其制备方法和用途 |
| CN115746157B (zh) * | 2022-11-24 | 2023-08-08 | 吉林农业大学 | 一种美味扇菇多糖及其制备方法和用途 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108047349B (zh) | 2020-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100847104B1 (ko) | 아토피 피부염 개선제 조성물 | |
| Gao et al. | Antioxidant and immunological activity in vitro of polysaccharides from Gomphidius rutilus mycelium | |
| TWI301069B (en) | Edible tremella polysaccharide for skin care | |
| WO2020177390A1 (zh) | 一种猴头菌发酵制备含麦角硫因的化妆品原液的方法 | |
| Li et al. | Physicochemical characteristics and biological activities of polysaccharide fractions from Phellinus baumii cultured with different methods | |
| CN108047349A (zh) | 一种卷边桩菇多糖提取物及其制备方法和医用用途 | |
| KR101773081B1 (ko) | 저분자 사포닌 함량이 증대된 돌외 발효 추출물의 제조방법 | |
| KR101625163B1 (ko) | 자연동굴 조건에서 발효시킨 차가버섯 발효 추출물을 포함하는 화장료 조성물 | |
| KR20190060511A (ko) | 갈색거저리 발효 추출물을 유효성분으로 포함하는 항산화용 조성물 | |
| CN111704678A (zh) | 一种平菇半乳甘露葡聚糖及其制备方法和用途 | |
| CN111321183A (zh) | 具抗癌抗病毒抗发炎、促进成骨细胞增生促进肠道干细胞增生的多糖发酵组合物及制备方法 | |
| CN114874344A (zh) | 青稞嫩叶碱提多糖的制备方法及其应用 | |
| CN105175568A (zh) | 一种提取银杏白果多糖的方法及其产品 | |
| KR101458274B1 (ko) | 인삼 발효추출물을 함유하는 화장료 조성물 | |
| CN103739731A (zh) | 树脂吸附法脱除香菇多糖农药残留和重金属残留方法 | |
| CN116515005B (zh) | 羊肚菌多糖及其制备方法和在制备用于预防和/或改善抗抑郁症的药物中的应用 | |
| Zhao et al. | In vitro antioxidant and antitumor activities of polysaccharides extracted from the mycelia of liquid-cultured Flammulina velutipes | |
| JP5390589B2 (ja) | 血管新生阻害剤 | |
| CN104861080A (zh) | 番石榴中的多糖及其制备方法和用途 | |
| CN114404460A (zh) | 杨叶肖槿内生真菌发酵提取物及其制备方法与应用 | |
| CN113754791A (zh) | 一种白及多糖物质及其制备方法与应用 | |
| KR20120007170A (ko) | 닥나무 또는 그 추출물의 발효방법, 그 발효 추출물 및 이를 포함하는 화장료 조성물 | |
| Lee et al. | Antitumor and antioxidant activities of the extracts from fruiting body of Phellinus linteus | |
| KR100729213B1 (ko) | 면역 증강 활성을 갖는 잎새 버섯의 액체배양물로부터분리한 세포외 생체고분자 | |
| CN110585075A (zh) | 一种含皮肤美白因子的蘑菇提取物的制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20201027 |